SOLID BIOSCIENCES INC (SLDB) Stock Price, Quote, News and Overview
NASDAQ:SLDB - Nasdaq - US83422E2046 - Common Stock - Currency: USD
SLDB Quote, Performance and Key Statistics
2.89
+0.19 (+7.04%)
The current stock price of SLDB is 2.89 USD. In the past month the price decreased by -21.25%. In the past year, price decreased by -62.9%.
SLDB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 17.77 | 322.91B | ||
| AMGN | AMGEN INC | 13.1 | 146.19B | ||
| GILD | GILEAD SCIENCES INC | 13.79 | 132.89B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 111.58B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.47 | 64.44B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 37.59B | ||
| ARGX | ARGENX SE - ADR | 99.05 | 35.50B | ||
| ONC | BEIGENE LTD-ADR | 5.93 | 25.74B | ||
| BNTX | BIONTECH SE-ADR | N/A | 23.82B | ||
| NTRA | NATERA INC | N/A | 20.73B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.14B | ||
| BIIB | BIOGEN INC | 7.98 | 18.51B |
Related stock screener links
About SLDB
Company Profile
Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. The company is headquartered in Charlestown, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2018-01-26. The firm is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. The firm also has two cardiac pipeline gene transfer programs, SGT-601 for TNNT2 DCM and SGT-701 for RBM20 DCM, that are both in early preclinical development. The company also has a neuromuscular gene transfer program for the treatment of Friedreich's ataxia. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including novel capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Company Info
SOLID BIOSCIENCES INC
500 Rutherford Avenue, 3rd Floor
Charlestown MASSACHUSETTS 02139 US
CEO: Ilan Ganot
Employees: 100
Phone: 16173374680
SOLID BIOSCIENCES INC / SLDB FAQ
What is the stock price of SOLID BIOSCIENCES INC today?
The current stock price of SLDB is 2.89 USD. The price increased by 7.04% in the last trading session.
What is the ticker symbol for SOLID BIOSCIENCES INC stock?
The exchange symbol of SOLID BIOSCIENCES INC is SLDB and it is listed on the Nasdaq exchange.
On which exchange is SLDB stock listed?
SLDB stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SOLID BIOSCIENCES INC stock?
18 analysts have analysed SLDB and the average price target is 17.68 USD. This implies a price increase of 511.76% is expected in the next year compared to the current price of 2.89. Check the SOLID BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SOLID BIOSCIENCES INC worth?
SOLID BIOSCIENCES INC (SLDB) has a market capitalization of 223.97M USD. This makes SLDB a Micro Cap stock.
How many employees does SOLID BIOSCIENCES INC have?
SOLID BIOSCIENCES INC (SLDB) currently has 100 employees.
What are the support and resistance levels for SOLID BIOSCIENCES INC (SLDB) stock?
SOLID BIOSCIENCES INC (SLDB) has a support level at 2.59 and a resistance level at 2.96. Check the full technical report for a detailed analysis of SLDB support and resistance levels.
Should I buy SOLID BIOSCIENCES INC (SLDB) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SLDB, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SLDB, evaluating the profitability, health, valuation and growth aspects
- SOLID BIOSCIENCES INC (SLDB) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SOLID BIOSCIENCES INC (SLDB) Sales and EPS estimates to see what analysts future expectations are.
- SOLID BIOSCIENCES INC (SLDB) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SOLID BIOSCIENCES INC (SLDB) Insider and Institutional Ownership to learn about the owners and their transactions.
- SOLID BIOSCIENCES INC (SLDB) Stock Chart to make your own analysis
- SOLID BIOSCIENCES INC (SLDB) Latest news and press-releases to stay up to date.
Does SOLID BIOSCIENCES INC (SLDB) stock pay dividends?
SLDB does not pay a dividend.
When does SOLID BIOSCIENCES INC (SLDB) report earnings?
SOLID BIOSCIENCES INC (SLDB) will report earnings on 2025-08-11, before the market open.
What is the Price/Earnings (PE) ratio of SOLID BIOSCIENCES INC (SLDB)?
SOLID BIOSCIENCES INC (SLDB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.04).
What is the Short Interest ratio of SOLID BIOSCIENCES INC (SLDB) stock?
The outstanding short interest for SOLID BIOSCIENCES INC (SLDB) is 10.91% of its float. Check the ownership tab for more information on the SLDB short interest.
SLDB Technical Analysis
SLDB Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SLDB. SLDB scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
SLDB Financial Highlights
Over the last trailing twelve months SLDB reported a non-GAAP Earnings per Share(EPS) of -3.04. The EPS increased by 36.67% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -39.26% | ||
| ROE | -46.93% | ||
| Debt/Equity | 0 |
SLDB Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to SLDB. The Buy consensus is the average rating of analysts ratings from 18 analysts.